Introduction {#sec1_1}
============

Obesity is one of the greatest health-related challenges of the 21st century. According to data of the International Association for the Study of Obesity (IASO), Germany ranks first for prevalence of obesity in both sexes \[[@B1]\]. The German Federal Office of Statistics revealed that in 2009 51.4% of the population were overweight or obese. The average body mass index (BMI) of the German population in 2009 was 25.7 kg/m^2^, with 60.1% of men and 42.9% of women overweight \[[@B2]\]. Life expectancy is markedly shortened by obesity, in particular in young obese persons. The mortality risk rises to between 6-and 12-fold of that of the normal population, with a 12-year reduction in life expectancy for overweight men and 9-year reduction for women. For grade III obesity, a 20-year statistically corroborated reduction in life expectancy has been identified \[[@B3]\]. Surgical measures were compared in studies with conservative treatment. The results of the Swedish Obesity Subject (SOS) Study, which demonstrated the long-term effects of weight reduction on resolution of comorbidities, attest to the marked superiority of surgical treatment measures \[[@B4],[@B5]\]. Gender-specific aspects have implications for the complication rate, weight reduction, and resolution of comorbidities. The aim of the present study was to compare the data available from the German Bariatric Surgery Registry (GBSR) with international data with regard to gender-specific aspects.

Material and Methods {#sec1_2}
====================

The data from the GBSR have been registered prospectively in an online database since January 1, 2005 at the Institute for Quality Assurance in Surgical Medicine of the Otto-von-Guericke University Magdeburg, Germany \[[@B6]\]. This paper evaluates the data on the main performed operations, gastric banding (GB), sleeve gastrectomy (SG), and Roux-en-Y gastric bypass (RYGB), collected between 2005 and 2012, in terms of gender-specific aspects. This study is part of an ongoing multicenter observational study initiated on January 1, 2005 for quality assurance in obesity surgery. All hospitals conducting bariatric surgery in Germany are encouraged to register with the study and enter prospective patient data in an online database. Indication and surgical approach are based on the individual center\'s clinical practice. Information on the type of surgery (primary or secondary), surgical technique, anthropometric measures, vital and biochemical parameters, comorbidities, and short- and long-term complications is collected at the time of procedure and at annual follow-ups by the individual institutions in a standardized fashion. Short-term complications are classified as: i) intraoperative (injury of the spleen, liver, choledochus or vasculature, pneumothorax, gastric perforation, bleeding, or others), ii) general postoperative (urinary tract infection, renal complications, cardiac events, pulmonary complications, fever, thrombosis, or others), and iii) specific postoperative (bleeding requiring transfusion, bleeding requiring surgical revision, need for gastroscopy, insufficiency of anastomosis, stenosis of anastomoses, mechanical ileus, sepsis, peritonitis, intra-abdominal abscess, wound dehiscence, aseptic wound healing disorder, or others).

To ascertain completeness of data entry, participation in the study is a prerequisite to an institution\'s certification as a center for bariatric surgery, and reported case numbers are verified against a hospital\'s clinical and billing documentation. The anonymized data is provided to the institutions, and serves as a center\'s quality control in regards to surgical indication, complication rates, outcome, and follow-up in comparison with other centers. To optimize the quality and integrity of the registry data (e.g. minimize missing data and ensure adherence to eligibility criteria), statistical plausibility checks are employed, and regular random audits are conducted by the study director.

The study period ranged from January 1, 2005 to December 31, 2012. 137 centers participated. Patients who underwent a primary bariatric procedure in this time period were included in a descriptive statistical analysis performed by an independent statistical consulting firm (StatConsult, Magdeburg, Germany).

All computations were performed using SAS® 9.2 (SAS Institute, Cary, NC, USA) with a type 1 error rate of p \< 0.05. Baseline and individual time-point data were compared by robust t-test for continuous variables (weight, BMI, age), or by chi-square test for nominal data (presence of comorbidities, gender). Intra-subject comparisons of pre- and postoperative data were performed by paired t-test (weight, BMI). Outcomes of surgical procedures were compared by one-way analysis of variance (ANOVA) (weight, BMI).

The study was conducted according to the Recommendations of the Declaration of Helsinki for Biomedical Research and the Guidelines and Standards of the Institutional Review Boards. All patients provided informed consent prior to entering the study. Aspects studied included demographic data, surgical parameters, complications, mortality, weight loss, and amelioration of comorbidities following GB, SG, and RYGB with respect to incidence in men and women. A comparison of the results with the literature was performed.

Results {#sec1_3}
=======

The numbers of GB, SG, and RYGB as well as the gender distribution are illustrated in figure [1](#F1){ref-type="fig"}.

Demographic Data {#sec2_1}
----------------

With regard to gender distribution for bariatric procedures, and in particular for GB, SG, and RYGB, the proportion of women was higher. The mean age of women compared to that of men was significantly lower for all procedures. Female patients had a significantly lower BMI. Table [1](#T1){ref-type="table"} shows the demographic data for all GB, SG, and RYGB patients as well as those comparing men and women. Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} show the distribution of age and BMI for patients in relation to the three bariatric procedures.

Comorbidities {#sec2_2}
-------------

Comorbidities were recorded for all patients. Patients with SG and RYGB had a greater number of comorbidities than all other patients undergoing obesity surgery and registered in the GBSR. In the entire study, 79.5% of patients with GB, 89.9% of patients with SG, and 86.7% of patients with RYGB suffered from comorbidities. The percentage of comorbidities in men compared to women was higher if SG or RYGB were performed. Independent of the type of operation, male patients generally had a significantly higher incidence of hypertension, non-insulin-dependent diabetes mellitus type II (NIDDM), and sleep apnea. Incidence of hypertension was 59.4% in male GB patients, 73.1% in male SG patients, and 69.6% in male RYGB patients. For insulin-dependent diabetes mellitus type II (IDDM), female patients had a significantly lower incidence than male patients, with 4.6 versus 8.9% for GB, 11.1 versus 17.9% for SG, and 9.1 versus 17.3% for RYGB. The prevalence of sleep apnea in female and male patients was 8.6 versus 25.5% (p \< 0.001) with GB, 19.1 versus 39.8% (p \< 0.001) with SG, and 14.6 versus 37.1% (p \< 0.001) with RYGB. No significant gender-specific differences were detected for the occurrence of skeletal diseases and pulmonary embolism. The gender-specific proportions of comorbidities are given in table [2](#T2){ref-type="table"}.

Data on Surgical Technique {#sec2_3}
--------------------------

Since 2005, data have been recorded for GB and RYGB, and since 2006 for SG. GB is currently performed in 45, SG in 93, and RYGB in 85 of the participating hospitals. More than 98% of all primary bariatric procedures were performed using laparoscopy. No gender-specific differences were noted in terms of the access route. Clinically not relevant was the 8-min significantly longer operation time for male patients (p \< 0.001).

General Postoperative Complication Rates {#sec2_4}
----------------------------------------

The overall general complication rate for GB was 1.66% (n = 62) with a gender-specific difference. Male patients developed more general complications than females. This included cardiac complications and fever lasting longer than 2 days. The overall general postoperative complication rate for patients with SG was 6.10% (n = 506) without any gender-specific difference. Besides urinary infection, there was no significant difference in the general postoperative complication rate between men and women (table [3](#T3){ref-type="table"}). Patients with RYGB developed significantly more complications than patients with GB (p \< 0.001). The general postoperative complication rate was significantly higher for male (7.12%; n = 165) than for female (5.29%; n = 424) patients. Male patients developed significantly more cardiac and pulmonary complications than females (table [3](#T3){ref-type="table"}).

Specific Severe Postoperative Complications {#sec2_5}
-------------------------------------------

As specific severe complications, leakage or gastric perforation, bleeding, wound infection, and stenosis were considered. Special complications occurred in 43 out of 3,741 (1.15%) patients with GB. There was no gender-specific difference in the special complication rate (p = 0.101) (table [4](#T4){ref-type="table"}). The incidence of postoperative severe complications after SG was 4.87% (n = 404). A gender-specific aspect was detected for the incidence of bleeding necessitating reoperation, leakage, as well as sepsis and peritonitis. For RYGB, the overall specific complication rate was 5.30%. Specific complications occurred in 547 out of 10,331 patients. The specific complication rate was significantly higher in men (6.34%, n = 147) than in women (4.99%, n = 400) (p = 0.0011). Significant differences were detected for leakage or insufficiency of gastrojejunal anastomosis, sepsis, and peritonitis (table [4](#T4){ref-type="table"}).

Mortality {#sec2_6}
---------

Between January 1, 2005 and December 31, 2012, no patient died following primary GB. However, the mortality rate was 0.35% (n = 29) for SG and 0.27% (n = 28) for RYGB. For SG and RYGB, we found a higher mortality rate for men than for women (table [5](#T5){ref-type="table"}).

Follow-Up Data on Weight Reduction and Amelioration of Comorbidities {#sec2_7}
--------------------------------------------------------------------

The mean BMI reduction for patients with GB 3 years after operation was 10.9 kg/m^2^. The comparison between men and women showed a slightly higher mean BMI reduction for the female population, but the result was not statistically significant. Male patients were able to reduce their mean BMI from 49.0 kg/m^2^ to 37.2 kg/m^2^ (-11.8 kg/m^2^), and female patients from 45.6 kg/m^2^ to 35.0 kg/m^2^ (-10.6 kg/m^2^) (table [6](#T6){ref-type="table"}). For patients with SG, the mean BMI reduction 3 years after operation was 15.1 kg/m^2^ in male patients. This was slightly less than in female patients (16.1 kg/m^2^), without any statistical significance (table [6](#T6){ref-type="table"}). Within 3 years of RYGB, male patients lost 15.8 kg/m^2^ and female patients 16.1 kg/m^2^ (table [6](#T6){ref-type="table"}). Amelioration rates for IDDM, NIDDM, hypertension, and sleep apnea after GB, SG, and RYGB are shown in table [7](#T7){ref-type="table"}.

Discussion {#sec1_4}
==========

Since January 1, 2005, primary and revision bariatric procedures have been recorded within the framework of the GBSR by the Institute for Quality Assurance in Surgical Medicine at the Otto-von-Guericke University Magdeburg, with the aim of improving quality of care \[[@B6]\].

GB is still one of the most frequently performed bariatric operations worldwide, constituting about 17.1% of all bariatric procedures. Due to the experience with GB and the long-term effects, the operation rate in Europe and across the world has decreased \[[@B7]\]. In Germany, the number of GB procedures has decreased rapidly since 2005. Important reasons for this are the high BMI (overall mean BMI 49.9 kg/m^2^) and incidence of comorbidities in bariatric surgery patients in Germany. Less than 12% of all patients in Germany are free from comorbidities. In a literature review comparing GB, RYGB, and SG, the complication rate was 12.1% for SG, 9.5% for RYGB, and 6.5% for GB \[[@B8]\]. Long-term effects of GB have been reported in a systematic review which showed that 15 years after GB an almost 50% reduction in excess weight was maintained \[[@B9]\]. This review and the included reports did not contain information on gender-specific aspects of weight loss, amelioration of comorbidities, and reoperation rate. However, GB is a safe and less invasive technique showing no difference in long-term results when compared with RYGB \[[@B9]\]. There are no studies with follow-up data for more than 5 years concerned with gender-specific aspects after GB.

SG gained high popularity in Germany. Worldwide, 27.6% of all bariatric operations performed in 2011 were SGs \[[@B7]\]. This operation not only leads to a restriction of food intake but, due to resection of the fundus, also to less ghrelin production and hence a reduced feeling of hunger. In the bariatric treatment concept, SG is an effective procedure. It was first used as a first-stage procedure in high-risk patients in preparation for duodenal switch, and for patients with a BMI of more than 60 kg/m^2^\[[@B10]\]. However, SG is being increasingly performed as a stand-alone obesity surgery, especially as an alternative to RYGB \[[@B7],[@B11],[@B12]\]. However, there are only few studies with long-term follow-up data for more than 5 years \[[@B13],[@B14],[@B15]\]. To evaluate other factors influencing complications secondary to SG, data from the GBSR were analyzed in regard to gender-specific aspects. We evaluated a higher specific complication rate, especially for bleeding necessitating reoperation, leakage, and sepsis and peritonitis for male patients, as well as a significantly higher mortality rate. Because of their higher BMI and significantly higher incidence of comorbidities, men have a significantly higher overall complication rate and mortality. Therefore, in particular for men aged over 45 years, with a BMI above 55 kg/m^2^, hypertension, and/or sleep apnea, the indication for bridging through implantation of a balloon system should be investigated before resorting to SG \[[@B16]\].

GBSR data for gender-specific aspects of RYGB have shown a significant difference for anastomotic insufficiency of gastroenteroanastomosis. The leakage rate for men was 2.37% (55/2,317) and for women 1.68% (135/8,013). Studies with multivariate analysis for RYGB revealed a higher mortality rate for patients with the following characteristics: male gender (odds ratio (OR) 2.80), BMI \> 50 kg/m^2^ (OR 3.60), hypertension (OR 2.78), pulmonary embolism (OR 2.62), and age above 45 years (OR 1.64) \[[@B17]\]. Because of the abdominal obesity prevalent in men, the operation often poses a technical challenge. This is due to the narrow intra-abdominal space. Further studies focusing on hand-assisted laparoscopic RYGB showed that the higher incidence of comorbidities in male patients is not associated with higher perioperative morbidity and mortality rates \[[@B18]\].

The protective effect of the female gender on the complication and mortality rate has been discussed since 2005. Currently, little attention is paid to gender-specific aspects for indication and selection of the surgical technique, especially in obesity and metabolic surgery \[[@B16],[@B19],[@B20]\]. The present evaluation shows that men undergoing GB, SG, and RYGB in Germany have a significantly higher BMI than women. Furthermore, it has been shown that decisive changes occurring in inflammatory parameters of male patients are correlated with increased morbidity \[[@B21]\]. An important aspect in the discussion and evaluation of risk parameters is the presence of comorbidities. The findings of the GBSR show that men have significantly more comorbidities than women. Compared with female patients, male patients undergoing GB, SG, and RYGB have a significantly higher incidence of hypertension, IDDM, and sleep apnea. The higher incidence of preoperative comorbidities in men results in a lower remission rate of hypertension, sleep apnea, and NIDDM. Data also show that male patients have to lose significantly more weight than female patients to reach a total remission of hypertension and sleep apnea (not so for diabetes). These results indicate that further discussion is needed about whether GB should be the procedure of choice in male patients with hypertension, diabetes mellitus type II, and sleep apnea. A bias exists in the data of the GBSR in that the onset and duration of the comorbidities have not been evaluated, with the further problem of the low number of patients with follow-up data.

A meta-analysis demonstrated that with a female proportion of 85% for all obesity surgeries, the 30-day mortality was 0.1% for women vs. 4.7% for men (p \< 0.001) \[[@B15]\]. The data of the GBSR also shows a significantly higher mortality rate for men than for women after SG and RYGB. Several factors have been proposed to explain the increased morbidity and mortality in male patients. As a further bias of the GBSR, we ought to highlight that with respect to mortality the learning effect is dependent on volume \[[@B22]\]. To obtain evidence-based data on mortality, there is therefore a need for propensity score analyses of the same patient collective with regard to BMI, comorbidities, and operating time.

Conclusion {#sec1_5}
==========

Based on the data of the GBSR study, it was possible to demonstrate that female gender has a protective effect against complications. Because of their higher BMI and significantly higher incidence of comorbidities, men have a significantly higher overall complication rate and mortality. There are no studies with follow-up data for more than 5 years regarding gender-specific aspects after the different bariatric operations. The aim of the GBSR is to evaluate these data and compare GB, SG, and RYGB over a time period of at least 10 years.
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###### 

Demographic data -- mean age and BMI

  Operation                  Sex     p       
  -------------------------- ------- ------- ---------
  Gastric banding                            
   Patients, n               2,860   881     \<0.001
   Mean age, years           40.1    42.6    \<0.001
   Mean BMI, kg/m^2^         44.8    46.4    \<0.001
  Sleeve gastrectomy                         
   Patients, n               5,322   2,971   \<0.001
   Mean age, years           42.9    44.7    \<0.001
   Mean BMI, kg/m^2^         51.6    53.1    \<0.001
  Roux-en-Y gastric bypass                   
   Patients, n               8,013   2,317   \<0.001
   Mean age, years           41.3    43.9    \<0.001
   Mean BMI, kg/m^2^         48.1    48.6    \<0.001

###### 

Gender-specific distribution of comorbidities

  Comorbidities               Sex, %   p      
  --------------------------- -------- ------ ---------
  None                                        
   Gastric banding            21.6     17.8   0.002
   Sleeve gastrectomy         11.3     8.4    \<0.001
   Roux-en-Y gastric bypass   14.5     9.3    \<0.001
  Hypertension                                
   Gastric banding            44.0     59.4   \<0,001
   Sleeve gastrectomy         60.8     73.1   \<0.001
   Roux-en-Y gastric bypass   54.2     69.6   \<0.001
  IDDM                                        
   Gastric banding            4.6      8.9    \<0.001
   Sleeve gastrectomy         11.1     17.9   \<0.001
   Roux-en-Y gastric bypass   9.1      17.3   \<0.001
  NIDDM                                       
   Gastric banding            11.5     16.9   \<0.001
   Sleeve gastrectomy         21.1     23.5   0.013
   Roux-en-Y gastric bypass   21.3     26.3   \<0.001
  Pulmonary comorbidity                       
   Gastric banding            12.7     16.0   \<0.001
   Sleeve gastrectomy         20.4     22.1   0.074
   Roux-en-Y gastric bypass   18.2     18.7   0.548
  Pulmonary embolism                          
   Gastric banding            1.1      1.2    0.964
   Sleeve gastrectomy         1.1      1.1    0.895
   Roux-en-Y gastric bypass   0.5      0.8    0.120
  Sleep apnea                                 
   Gastric banding            8.6      25.5   \<0.001
   Sleeve gastrectomy         19.1     39.8   \<0.001
   Roux-en-Y gastric bypass   14.6     37.1   \<0.001
  Skeletal disease                            
   Gastric banding            42.9     42.0   0.648
   Sleeve gastrectomy         49.1     46.1   0.008
   Roux-en-Y gastric bypass   40.5     39.8   0.583

###### 

Incidence of general postoperative complications

  Complications              Sex     p       
  -------------------------- ------- ------- ---------
  Gastric banding                            
   Patients, n               2,860   881     \<0.001
   Cardiac, %                0.03    0.34    0.043
   Pulmonary, %              0.23    0.21    1.000
   Urinary infection, %      0.07    0.0     1.000
   Fever, %                  0.14    0.57    0.038
   Thromboembolism, %        0.07    0.00    1.000
   Total, %                  1.40    2.50    0.034
  Sleeve gastrectomy                         
   Patients, n               5,322   2,971   \<0.001
   Cardiac, %                0.43    0.71    0.115
   Pulmonary, %              1.09    1.21    0.665
   Urinary infection, %      1.39    0.50    \<0.001
   Fever, %                  1.45    1.99    0.071
   Thromboembolism, %        0.08    0.10    0.707
   Total, %                  5.99    6.29    0.599
  Roux-en-Y gastric bypass                   
   Patients, n               8,013   2,317   \<0.001
   Cardiac, %                0.36    0.91    0.002
   Pulmonary, %              0.95    1.51    0.029
   Urinary infection, %      0.96    0.47    0.028
   Fever, %                  1.55    2.16    0.054
   Thromboembolism, %        0.04    0.09    0.219
   Total, %                  5.29    7.12    0.001

###### 

Gender-specific postoperative complications

  Complications                 Sex     p       
  ----------------------------- ------- ------- ---------
  Gastric banding                               
   Patients, n                  2,860   881     \<0.001
   Intraoperative bleeding, %   0.00    0.23    0.055
   Leakage, %                   0.07    0.11    0.553
   Stenosis, %                  0.17    0.11    1.000
   Ileus, %                     0.07    0.23    0.237
   Sepsis, %                    0.03    0.11    0.416
   Peritonitis, %               0.07    0.34    0.089
   Wound infection, %           0.42    0.68    0.401
   Total, %                     0.98    1.70    0.101
  Sleeve gastrectomy                            
   Patients, n                  5,322   2,971   \<0.001
   Intraoperative bleeding, %   1.11    1.72    0.027
   Leakage, %                   1.50    2.12    0.043
   Stenosis, %                  0.17    0.07    0.347
   Ileus, %                     0.10    0.04    0.357
   Sepsis, %                    0.91    0.49    0.030
   Peritonitis, %               0.98    0.45    0.006
   Wound infection, %           0.81    0.92    0.626
   Total, %                     5.35    4.60    0.136
  Roux-en-Y gastric bypass                      
   Patients, n                  8,013   2,317   \<0.001
   Intraoperative bleeding, %   0.62    0.99    0.067
   Leakage, %                   1.68    2.37    0.035
   Stenosis, %                  0.59    0.73    0.452
   Ileus, %                     0.30    0.49    0.290
   Sepsis, %                    0.82    0.41    0.019
   Peritonitis, %               1.04    0.70    0.107
   Wound infection, %           0.99    1.01    1.000
   Total, %                     6.34    4.99    0.011

###### 

Mortality rates

                             Operations, n   Mortality, n (%)   p
  -------------------------- --------------- ------------------ ----------------
  Gastric banding                                               not assessable
   Men                       881             0 (0)              
   Women                     2,860           0 (0)              
  Sleeve gastrectomy                                            \<0.001
   Men                       2,971           20 (0.68)          
   Women                     5,322           9 (0.17)           
  Roux-en-Y gastric bypass                                      0.002
   Men                       2,317           14 (0.61)          
   Women                     8,013           14 (0.18)          

###### 

Mean reduction in BMI from time of surgery to last follow-up based on procedure

                                             Sex    
  ------------------------------------------ ------ ------
  Gastric banding                                   
   Patients, n                               122    40
   Mean BMI at operation, kg/m^2^            45.6   49.0
   Mean BMI 1 year postoperative, kg/m^2^    38.4   40.9
   Mean BMI 3 years postoperative, kg/m^2^   35.0   37.2
  Sleeve gastrectomy                                
   Patients, n                               214    65
   Mean BMI at operation, kg/m^2^            49.0   50.2
   Mean BMI 1 year postoperative, kg/m^2^    35.6   37.3
   Mean BMI 3 years postoperative, kg/m^2^   32.7   35.1
  Roux-en-Y gastric bypass                          
   Patients, n                               105    66
   Mean BMI at operation, kg/m^2^            52.5   53.5
   Mean BMI 1 year postoperative, kg/m^2^    38.4   39.4
   Mean BMI 3 years postoperative, kg/m^2^   36.4   37.7

###### 

Gender-specific amelioration rates of comorbidities after GB, SG, and RYGB

                               Sex, %   
  ---------------------------- -------- ------
  *Gastric banding*                     
   IDDM                                 
    Remission                  59.1     60.7
    Increase                   12.5     12.5
    Without change             28.4     26.8
   NIDDM                                
    Remission                  68.9     58.6
    Increase                   3.4      2.0
    Without change             27.6     39.4
   Hypertension                         
    Remission                  53.6     45.6
    Increase                   5.0      4.2
    Without change             41.4     50.2
   Sleep apnea                          
    Remission                  62.0     50.9
    Increase                   3.1      4.5
    Without change             34.8     44.5
  *Sleeve gastrectomy*                  
   IDDM                                 
    Remission                  76.9     76.0
    Increase                   7.4      8.5
    Without change             15.7     15.5
   NIDDM                                
    Remission                  78.9     76.8
    Increase                   4.7      7.3
    Without change             16.4     15.8
   Hypertension                         
    Remission                  63.0     63.1
    Increase                   2.8      2.7
    Without change             34.1     34.2
   Sleep apnea                          
    Remission                  67.5     66.7
    Increase                   5.5      4.4
    Without change             27.0     28.8
  *Roux-en-Y gastric bypass*            
   IDDM                                 
    Remission                  81.2     83.1
    Increase                   10.3     7.4
    Without change             8.4      9.5
   NIDDM                                
    Remission                  87.1     82.6
    Increase                   5.8      7.5
    Without change             7.1      9.9
   Hypertension                         
    Remission                  74.0     73.2
    Increase                   3.5      3.4
    Without change             22.4     23.4
   Sleep apnea                          
    Remission                  74.9     72.2
    Increase                   3.6      3.9
    Without change             21.5     23.9
